medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2026, Number 2

<< Back Next >>

Acta Med 2026; 24 (2)

Prevalence of malignant bone tumors in “General Ignacio Zaragoza” ISSSTE Regional Hospital

Braña RK, Mora RFG, Alanis NML, Domínguez GRC, Rosas MR, Millán DG, Pérez JEI

Language: Spanish
References: 18
Page: 102-107
PDF size: 249.84 Kb.


ABSTRACT

Introduction: malignant bone tumors constitute a heterogeneous group of neoplasms, representing between 15 and 20% of malignant bone lesions. Objective: to know the prevalence of malignant bone tumors in ISSSTE Regional Hospital “General Ignacio Zaragoza”. Material and methods: a sample of 199 patients was obtained between 2018 and 2023, and the data were collected for subsequent statistical analysis. Results: 102 women (51.3%) and 97 men (48.7%), with a higher prevalence in middle-aged adults (39.7%), followed by children and older adults (22.6% each), and young adults (15.1%). Osteosarcomas and Ewing sarcomas are more frequent in young patients. Chondrosarcomas and metastases are more common in older adults. Conclusion: the insights derived from this study facilitate progress toward a more efficient and targeted management of malignant bone tumors, along with their contribution to knowledge about epidemiology of malignant bone tumors and their potential impact on improving the diagnosis and treatment of these conditions.


REFERENCES

  1. Schajowicz F. Histological typing of bone tumors. World HealthOrganization International Histological Classification of Tumors.Berlin: Springer-Verlag; 1993.

  2. Boyer MI, editor. Sección 4. Patología oncológica y sistemática. En:AAOS Comprehensive Orthopaedic Review 2. edición en español.American Academy of Orthopaedic Surgeons; 2014.

  3. Epidemiology of bone tumors in Mexico City: retrospectiveclinicopathologic study of 566 patients at a referral institution.Ann Diagn Pathol. 2009; 13 (1): 16-21. doi: 10.1016/j.anndiagpath.2008.07.005.

  4. Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, Szuhai K, BovéeJVMG. Molecular pathology of bone tumors. J Mol Diagn. 2019; 21(2): 171-182. doi: 10.1016/j.jmoldx.2018.11.002.

  5. Xu Y, Shi F, Zhang Y, Yin M, Han X, Feng J et al. Twenty-year outcomeof prevalence, incidence, mortality and survival rate in patients withmalignant bone tumors. Int J Cancer. 2024; 154 (2): 226-240. doi:10.1002/ijc.34694.

  6. Schulte M, Hartmann W. Knochentumoren des Kindes- undJugendalters [Bone tumors in children and adolescents]. Pathologie(Heidelb). 2023; 44 (6): 348-356. doi: 10.1007/s00292-023-01235-z.

  7. Survival outcomes in pediatric patients with metastatic Ewing sarcomawho achieve a rapid complete response of pulmonary metastases.Pediatr Blood Cancer. 2024; 71 (7): e31026. doi: 10.1002/pbc.31026.

  8. Engel H, Herget GW, Füllgraf H, Sutter R, Benndorf M, BambergF et al. Chondrogenic bone tumors: the importance of imagingcharacteristics. Rofo. 2021; 193 (3): 262-274.

  9. Coleman RE. Metastatic bone disease: clinical features, pathophysiologyand treatment strategies. Cancer Treat Rev. 2001; 27 (3): 165-176.

  10. Xi Y, Qiao L, Na B, Liu H, Zhang S, Zheng R et al. Primary malignantbone tumors incidence, mortality, and trends in China from 2000 to2015. Chin Med J (Engl). 2023; 136 (17): 2037-2043. doi: 10.1097/CM9.0000000000002547.

  11. Sadykova LR, Ntekim AI, Muyangwa-Semenova M, RutlandCS, Jeyapalan JN, Blatt N et al. Epidemiology and risk factorsof osteosarcoma. Cancer Invest. 2020; 38 (5): 259-269. doi:10.1080/07357907.2020.1768401.

  12. Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R et al.Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinicalpractice guideline for diagnosis, treatment and follow-up. Ann Oncol.2021; 32 (12): 1520-1536. doi: 10.1016/j.annonc.2021.08.1995.

  13. Ozturk R, Arikan SM, Bulut EK, Kekec AF, Celebi F, Güngor BS.Distribution and evaluation of bone and soft tissue tumors operatedin a tertiary care center. Acta Orthop Traumatol Turc. 2019; 53 (3):189-194. doi: 10.1016/j.aott.2019.03.008.

  14. Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y et al. Bone microenvironmentand osteosarcoma metastasis. Int J Mol Sci. 2020; 21 (19): 6985. doi:10.3390/ijms21196985.

  15. Jobke B, Werner M. Osteogenic tumors of bone. Radiologe. 2016;56 (6): 489-506. doi: 10.1007/s00117-016-0119-5.

  16. Govallo VI, Grigor’eva MP, Kosmiadi GA, Zatsepin ST. [Comparativeanalysis of immunoreactive indices in malignant and benign bonetumors]. Vopr Onkol. 1984; 30 (10): 19-25.

  17. Khan M, Patel R, Youssef M, Banerjee R, Pardiwala A, Belen C. Asystemic review of primary malignant long bone tumors in childrenand adolescents. Acta Chir Orthop Traumatol Cech. 2024; 91 (2):77-87. doi: 10.55095/ACHOT2024/010.

  18. Cecchini MG, Wetterwald A, Pluijm G van der, Thalmann GN.Molecular and biological mechanisms of bone metastasis. EAU UpdateSer. 2005; 3 (4): 214-226.




2020     |     www.medigraphic.com